program logo/macu/on light

BrightFocus Foundation Response to FDA Approval of New Vision Treatment

Food and Drug Administration Backs Longer-Lasting Drug for Macular Degeneration
  • Press Release
Published on:
A colorful graphic illustration of the eye.

The following statement was issued by Stacy Pagos Haller, BrightFocus President and CEO:

“The FDA approval of faricimab, to be marketed as Vabysmo™, is an important step forward for vision research, giving new hope for the millions at risk of losing their sight to age-related macular degeneration (AMD).

Vabysmo can improve the quality of life for those living with the neovascular (“wet”) form of AMD and diabetic macular edema, extending the time between treatments to up to four months. A key component of Vabysmo is rooted in the discoveries from pivotal, early-stage research supported by BrightFocus.

The FDA’s approval powerfully affirms the great progress scientists are making toward saving our sight. My deepest thanks to the many researchers and clinical trial volunteers who helped make this breakthrough possible.”



For more information on Vabysmo, go to or 866/422-2377

BrightFocus Foundation is a premier private funder of research and public awareness to defeat macular degeneration, glaucoma, and Alzheimer’s disease, currently supporting a $65 million global portfolio of over 260 scientific projects. For more information visit

Don't miss out.

Receive macular degeneration breakthrough news, research updates, and inspiring stories.